Skip to main content
Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
34.06
+0.30 (0.89%)
At close: Jan 17, 2025, 4:00 PM
35.61
+1.55 (4.55%)
Pre-market: Jan 21, 2025, 5:48 AM EST

Moderna Revenue by Segment
Period Ending Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Product Sales
4.96B 4.90B 5.01B 6.67B 8.77B 10.14B 14.37B 18.47B
Product Sales Growth
-43.42% -51.65% -65.15% -63.88% -57.23% -54.34% -34.27% 4.50%
Grant and Collaboration
117.00M 149.00M - 177.00M 384.00M 554.00M 721.00M 828.00M
Grant and Collaboration Growth
-69.53% -73.10% - -78.62% -56.31% -30.23% -1.64% 4.02%

Product Sales by Geography
Period Ending Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022
United States
2.28B 1.98B 1.82B 1.72B 1.94B 2.01B 3.46B 4.41B
United States Growth
17.52% -1.69% -47.44% -60.95% - - - -
Rest of World
1.79B 2.21B 2.41B 3.60B 3.84B 4.19B 5.65B 7.30B
Rest of World Growth
-53.39% -47.31% -57.24% -50.70% - - - -
Europe
895.00M - - 1.35B 2.96B 3.90B 5.23B 6.73B
Europe Growth
-69.76% - - -79.90% - - - -

Operating Expense Breakdown
Period Ending Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Research and Development
4.83B 4.85B 4.78B 4.85B 4.65B 4.31B 3.87B 3.30B
Research and Development Growth
3.81% 12.53% 23.37% 47.04% 70.20% 77.15% 80.60% 65.49%
Selling, General, and Administrative
1.29B 1.45B 1.52B 1.55B 1.45B 1.29B 1.17B 1.13B
Selling, General, and Administrative Growth
-11.07% 12.71% 29.85% 36.84% 51.77% 52.12% 54.22% 99.65%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.